Omnicell, Inc. (OMCL) Expected to Announce Earnings of $0.41 Per Share
Brokerages expect that Omnicell, Inc. (NASDAQ:OMCL) will announce earnings of $0.41 per share for the current quarter, Zacks reports. Three analysts have made estimates for Omnicell’s earnings, with the highest EPS estimate coming in at $0.43 and the lowest estimate coming in at $0.40. Omnicell reported earnings of $0.40 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.5%. The business is expected to report its next quarterly earnings results after the market closes on Thursday, October 26th.
On average, analysts expect that Omnicell will report full year earnings of $1.29 per share for the current year, with EPS estimates ranging from $1.28 to $1.32. For the next year, analysts forecast that the business will post earnings of $2.04 per share, with EPS estimates ranging from $2.00 to $2.11. Zacks’ EPS averages are an average based on a survey of research analysts that cover Omnicell.
Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 27th. The company reported $0.02 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.02. The business had revenue of $180.90 million for the quarter, compared to analysts’ expectations of $174.08 million. Omnicell had a return on equity of 0.76% and a net margin of 0.46%. The firm’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.38 earnings per share.
A number of research firms recently weighed in on OMCL. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research note on Thursday, October 19th. Benchmark Co. lifted their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. BidaskClub cut shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reiterated a “hold” rating and issued a $40.00 price target on shares of Omnicell in a research note on Sunday, July 30th. Finally, Dougherty & Co boosted their price target on shares of Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $51.86.
In other Omnicell news, Chairman Randall A. Lipps sold 37,500 shares of the business’s stock in a transaction on Friday, July 28th. The shares were sold at an average price of $46.00, for a total value of $1,725,000.00. Following the sale, the chairman now owns 196,551 shares in the company, valued at approximately $9,041,346. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Dan S. Johnston sold 16,400 shares of the business’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $48.86, for a total transaction of $801,304.00. Following the completion of the sale, the executive vice president now owns 51,621 shares in the company, valued at approximately $2,522,202.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 184,094 shares of company stock worth $9,094,791. Corporate insiders own 3.77% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Oppenheimer Asset Management Inc. purchased a new stake in shares of Omnicell during the 1st quarter valued at about $170,000. Turner Investments LLC purchased a new stake in shares of Omnicell during the 2nd quarter valued at about $181,000. Flinton Capital Management LLC raised its position in shares of Omnicell by 74.6% during the 2nd quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock valued at $182,000 after buying an additional 1,802 shares in the last quarter. Riverhead Capital Management LLC raised its position in shares of Omnicell by 76.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock valued at $182,000 after buying an additional 1,830 shares in the last quarter. Finally, Sei Investments Co. raised its position in shares of Omnicell by 36.4% during the 2nd quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock valued at $200,000 after buying an additional 1,242 shares in the last quarter.
Omnicell (OMCL) traded up 1.77% on Tuesday, reaching $54.50. The company had a trading volume of 266,408 shares. Omnicell has a 12-month low of $30.35 and a 12-month high of $55.40. The stock’s market capitalization is $2.04 billion. The stock’s 50 day moving average price is $50.74 and its 200-day moving average price is $45.70.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.